Is compounded semaglutide safe: what you need to know

Introduction

Compounded semaglutide is not FDA-approved. The FDA recommends it only when an approved drug cannot meet a patient’s medical needs. Before choosing a compounded product, discuss the risks and FDA-approved semaglutide options, including Ozempic and Wegovy, with your prescriber. [1]

What compounded semaglutide is

Compounding pharmacies can prepare drugs for an identified patient’s clinical needs under federal and state requirements. For example, a prescriber may determine that an FDA-approved product cannot meet a patient’s need because of a particular ingredient or dosage form. A compounded drug differs from an approved generic: the FDA does not review its safety, effectiveness, or quality before marketing. [4]

Some compounders use semaglutide sodium or semaglutide acetate. These salt forms differ from the active ingredient in FDA-approved Ozempic and Wegovy, and the FDA says it is not aware of any lawful basis for their use in compounding. Ask your pharmacy to confirm the ingredient and concentration. [1]

Why compounded semaglutide became popular

Demand and shortages made compounded GLP‑1 products more visible. Federal law allows qualifying compounding during drug shortages under specific conditions. Those provisions do not establish equivalence to an FDA-approved product. [2] [4]

Price and insurance coverage can also influence interest, but cash prices, savings programs, and plan coverage change frequently. Compare current total costs and eligibility using the official manufacturer and insurer information rather than relying on a fixed price quoted in an article.

The safety concerns

The FDA has identified several concerns with unapproved compounded GLP‑1 products:

• Dosing errors: Some patients needed hospital care after dosing errors; confusion between milligrams, milliliters, and syringe units may have contributed. Concentrations can differ between products, including products from the same compounder. Ask your pharmacist to demonstrate the prescribed dose using the syringe supplied with your medication. [3]
• Fraudulent labels: Some sellers name pharmacies that did not make the product. Obtain a prescription from a licensed prescriber and verify the dispensing pharmacy. [1]
• Shipping problems: Do not use injectable GLP‑1 medication that arrives warm or with inadequate refrigeration. Contact the dispensing pharmacy for help. [1]
• Added ingredients: The FDA says the safety and effectiveness of combining semaglutide with ingredients such as vitamin B12 have not been established. [3]

For compounded GLP‑1 multidose vials, the FDA generally recommends discarding the vial within 28 days of first use, even if medication remains or the compounder’s instructions allow longer use. Follow any earlier expiration or discard date. The FDA also advises using a new sterile needle and syringe for each dose. [1] [5]

What changed after February 2025

On February 21, 2025, the FDA declared the semaglutide injection shortage resolved. The temporary enforcement-discretion period for shortage-related copies ended for section 503A pharmacies in April 2025 and for section 503B outsourcing facilities on May 22, 2025. [2]

In April 2026, the FDA reiterated that section 503A restrictions on copies include an exception when a prescriber documents a change that makes a significant difference for an identified patient. Section 503B has separate restrictions on bulk ingredients; semaglutide does not currently appear on the relevant bulk-substances list or the shortage list. Ask your prescriber and pharmacy how your prescription meets current requirements. [2]

Questions to ask before using compounded semaglutide

If you are considering a compounded product, discuss these points with your prescriber:

• Pharmacy status: Is the pharmacy licensed in your state? If it says it is a 503B outsourcing facility, can you confirm that status in the FDA’s public list?
• Third-party testing: Does the pharmacy conduct independent testing for potency, sterility, and endotoxins on each batch?
• Ingredient and concentration: Is the active ingredient semaglutide base or a salt form? What is the concentration, and exactly how should the prescribed milligram dose be measured?
• Prescriber experience: Has your provider prescribed compounded GLP‑1 medications before, and do they have a monitoring plan for you?

Ask your pharmacist to check the concentration and dosing directions with each refill. Do not reuse a previous vial’s syringe-unit instructions without confirming they apply to the new vial. [3] A pharmacy’s answers or testing claims cannot establish that its product is equivalent to an FDA-approved medicine.

Brand-name alternatives for reducing cost

Ask your prescriber and insurer about current ways to access an FDA-approved treatment:

• Manufacturer savings programs: Eligibility and terms change, so use the manufacturer’s current program page.
• Prior authorization appeals: If your insurance initially denies coverage, your provider can submit a prior authorization with supporting documentation of medical necessity.
• Patient assistance programs: Ask whether you meet the current eligibility requirements.
• Other FDA-approved treatments: Your prescriber can assess whether another product is clinically appropriate and better covered by your plan.

Track your treatment with Shotsy

Shotsy tracks your doses, weight, and side effects in one place. A documented record is useful with compounded products, which may differ in concentration and quality; keep the pharmacy label and dosing instructions alongside your treatment records. [3] [4] Tracking supports discussions with your care team, but it cannot verify potency, sterility, or product safety.

Conclusion

Compounded semaglutide has risks that treatment logs cannot rule out. If your prescriber identifies a medical need for it, confirm the pharmacy, ingredient, concentration, dosing directions, and storage limits before use. Discuss available FDA-approved options and keep your care team informed about symptoms or problems with the medication.